Franco-Nevada Corporation acquired 10 million common shares of Kenorland Minerals, representing 12.42% of the company, for $22.2 million through private agreements. This marks Franco-Nevada's first investment in Kenorland, a mineral exploration company focused on North America. The transaction involved shares purchased from John Tognetti and Kenorland's CEO Zach Flood, who continues to hold shares post-sale. Franco-Nevada has no immediate plans to increase or decrease its stake but may adjust holdings based on market conditions in the future.
Franco-Nevada's stake in Kenorland Minerals is the focus, with Pluang data providing market context. As of Oct 06, 2026 03:02 WIB, 20 of 38 Basic Materials stocks rose, 18 fell. Notable movers include DOW at USD 28.52 (+1.95%), WPM at USD 136.00 (+1.93%, 64% buy orders), and KGC at USD 23.60 (-1.91%, 62% sell orders).
Revvity's stock has surged 56.1% year-to-date, outperforming its industry and the S&P 500, driven by an 11% organic revenue growth in diagnostics, especially in reproductive health and immunodiagnostics. Analysts from William Blair and Zacks have upg...
Levi Strauss & Co. is set to report its Q3 2026 earnings on October 7, with analysts forecasting adjusted earnings of $0.36 per share and revenue of $1.61 billion, marking a 4.5% increase year-over-year. Strong denim demand and growth in Europe, Asia...
On October 5, 2026, five notable stocks experienced double-digit declines. Sphere Entertainment fell 13.6% after a downgrade from Craig-Hallum, while C.H. Robinson dropped 10.9% following its announcement to acquire RXO for $5.8 billion. Velo3D, Boos...
Applied Digital is set to report a fiscal Q1 loss of $0.30 per share on $116.3 million revenue, reflecting ongoing investments in AI and high-performance data centers. The company has expanded its Polaris Forge 1 campus to 250 MW operational capacity...
Investment firm Needham increased its price target for Vaxcyte to $122 from $110 following positive Phase 3 trial results for Vaxcyte's VAX-31 pneumococcal vaccine. The vaccine met all primary endpoints in the OPUS-1 trial, showing noninferiority to ...
